TriSalus Life Sciences, Inc. announced a private placement that it has issued 6,167,776 shares of common stock, par value $0.0001 per share and 230,000 shares of common stock issuable upon conversion of shares of the Issuer?s Series A Convertible Preferred Stock on August 10, 2023. The transaction included participation from new investor, Frankenius Equity AB.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
6.03 USD | +1.17% | -15.78% | -28.64% |
Jun. 03 | TriSalus Life Sciences, Inc. Highlights Clinical Data from Phase 1b Perio-02 Trial | CI |
May. 30 | Canaccord Genuity Initiates TriSalus Life Sciences at Buy Rating With $12 Price Target | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-28.64% | 164M | |
+16.93% | 123B | |
+17.01% | 111B | |
-7.23% | 23.63B | |
+3.20% | 22.58B | |
-14.55% | 17.26B | |
-6.79% | 17.6B | |
-37.63% | 17.61B | |
+2.17% | 13.55B | |
+24.42% | 11.34B |
- Stock Market
- Equities
- TLSI Stock
- News TriSalus Life Sciences, Inc.
- TriSalus Life Sciences, Inc. announced that it has received funding from Frankenius Equity AB